

Announcing the Finalists of *The Scientist's* 10th Annual Best Places to Work in Industry Survey

(New York, NY) – June 1, 2012 – *The Scientist* magazine announced today the winners of its 10th annual “Best Places to Work in Industry” survey.

Coming in at #1 this year, is newcomer ADInstruments, a company founded in New Zealand that provides equipment and software for recording physiological signals. Epizyme and DuPont, which ranked as the #1 small and large company, respectively, in last year’s survey, followed ADInstruments, coming in at #2 and #3.

Much has changed in the 10 years since *The Scientist* first surveyed industry researchers. Those who responded to our first industry survey a decade ago said that they wanted nothing more than to work for a company that had integrity. This year, however, researchers say what they look for most in an employer is the ability to provide deep personal and scientific satisfaction—although high ethical standards still rank as the third most important factor.

Small companies excel at fostering scientific excellence and nurturing their employees, which is why it’s no surprise that six of the top 10 companies in this year’s survey have fewer than 200 employees. The #6-ranked Rib-X Pharmaceuticals, which develops novel antibiotic compounds based on the structure and function of the ribosome, is one such example. The company employs 43 people, many of whom have been with the company for more than a decade.

Over the past decade there’s been a change in business strategy for big pharmaceutical companies and smaller biotechs alike. In the face of shrinking revenue streams and the growing costs of drug development and clinical trials, larger companies are opting to outsource their resource and development (R&D) to the smaller, yet ever-growing biotech sector. Conversely, smaller companies are increasingly turning to big pharma to help shoulder the costs of taking their products down the development pipeline. As a result the line between the two has become blurred.

“Whether big or small, the 20 companies that topped our industry survey this year have proven resilient in the face of an ever-changing economic landscape,” says Cristina Luiggi, editor of this year’s survey.

Over the past year, companies scoring high in our survey have launched or advanced the development of a wide range of clinical products, including plague and botulinum neurotoxin vaccines (DynPort Vaccine Company, #9), treatments for eye disorders (Regeneron Pharmaceuticals, #13), and drugs for treating cystic fibrosis, and hepatitis C (Vertex Pharmaceuticals, #5).

More than 2,000 industry researchers responded to this year's survey. The full survey results and methodology will be detailed in the article "Best Places to Work in Industry, 2012," appearing in *The Scientist's* June issue and online at <http://www.the-scientist.com>. Members of the press who would like access to the full text or more information about *The Scientist's* Best Places to Work surveys should contact bptw@the-scientist.com.

The top 20 companies are:

1. ADInstruments, Bella Vista, NSW, Australia
2. Epizyme, Cambridge, MA
3. DuPont, Wilmington, DE
4. Wyatt Technology, Santa Barbara, CA
5. Vertex Pharmaceuticals, Cambridge, MA
6. Rib-X Pharmaceuticals, New Haven, CT
7. Dow AgroSciences, Indianapolis, IN
8. Genomatica, San Diego, CA
9. DynPort Vaccine Company, Frederick, MD
10. Pioneer Hi-Bred: A DuPont Business, Johnston, IA
11. Celldex Therapeutics, Needham, MA
12. Monsanto, St. Louis, MO
13. Regeneron Pharmaceuticals, Tarrytown, NY
14. Abbott Laboratories, Abbott Park, IL
15. Aldevron, Fargo, ND
16. Roche, Basel, Switzerland
17. Novartis, Basel, Switzerland
18. Alnylam Pharmaceuticals, Cambridge, MA
19. Integrated DNA Technologies (IDT), Coralville, IA
20. Bayer Corp, Leverkusen, Germany

ABOUT *THE SCIENTIST*

[The Scientist](#) has informed and entertained life science professionals around the world for over 25 years. We provide print and online coverage of the latest developments in the life sciences including trends in research, new technology, news, business and careers. We reach the leaders in academia and industry that are interested in maintaining a broad view of the life sciences by reading insightful articles that are current, concise and entertaining.